Pentoxifylline 200mg 20 tablets – Free Shipping
$18.00
Pentoxifylline 200mg 20 tablets
Produced in Ukraine
Free shipping
Description
Pharmacotherapeutic group: Peripheral vasodilators. Purine derivatives. ATX code C04A D03.
Composition:
active substance: pentoxifylline;
active substance: pentoxifylline;
1 tablet contains pentoxifylline 200 mg excipients: lactose, potato starch, calcium stearate.
Indications:
Atherosclerotic encephalopathy ischemic cerebral stroke; discirculatory encephalopathy; peripheral circulatory disorders caused by atherosclerosis, diabetes mellitus (including diabetic angiopathy), inflammation; trophic disorders in tissues associated with lesions of veins or impaired microcirculation (post-thrombophlebitic syndrome, trophic ulcers, gangrene, frostbite) obliterating endarteritis; angioneuropathy (Raynaud’s disease); impaired blood circulation of the eye (acute, subacute, chronic circulatory failure in the retina and choroid); impaired function of the inner ear of vascular origin, accompanied by hearing loss.
Atherosclerotic encephalopathy ischemic cerebral stroke; discirculatory encephalopathy; peripheral circulatory disorders caused by atherosclerosis, diabetes mellitus (including diabetic angiopathy), inflammation; trophic disorders in tissues associated with lesions of veins or impaired microcirculation (post-thrombophlebitic syndrome, trophic ulcers, gangrene, frostbite) obliterating endarteritis; angioneuropathy (Raynaud’s disease); impaired blood circulation of the eye (acute, subacute, chronic circulatory failure in the retina and choroid); impaired function of the inner ear of vascular origin, accompanied by hearing loss.
Contraindications:
Hypersensitivity to pentoxifylline, to other methylxanthines, or to any of the excipients; massive bleeding (risk of increased bleeding) hemorrhage in the retina; if during treatment with pentoxifylline there is a retinal hemorrhage, the use of the drug should be stopped immediately; cerebral hemorrhage; hemorrhagic diathesis; acute myocardial infarction; stomach ulcer and / or intestinal ulcers.
Hypersensitivity to pentoxifylline, to other methylxanthines, or to any of the excipients; massive bleeding (risk of increased bleeding) hemorrhage in the retina; if during treatment with pentoxifylline there is a retinal hemorrhage, the use of the drug should be stopped immediately; cerebral hemorrhage; hemorrhagic diathesis; acute myocardial infarction; stomach ulcer and / or intestinal ulcers.
Method of administration and dosage:
The drug should be prescribed 2-4 tablets 2-3 times a day. The tablets should be taken after meals, without chewing, with plenty of liquid. The maximum daily dose should not exceed 1200 mg. In case of arterial hypotension, negative reactions from the gastrointestinal tract or the central nervous system, the initial dose may be reduced to 100 mg of pentoxifylline 3 times a day. In case of impaired renal function (creatinine clearance <30 ml / min), the dose is reduced by 50-70%, according to individual sensitivity. Patients with severe hepatic dysfunction also need to reduce dosage according to individual sensitivity. In patients with arterial hypotension, as well as in patients at risk of a sharp decrease in blood pressure (for example, with damage to the coronary arteries or severe stenosis of the cerebral arteries), treatment should be started with low doses, gradually increasing them until the onset of a therapeutic effect. The drug in tablets can be prescribed as an adjunct to parenteral administration or as maintenance therapy after its administration. The duration of treatment is determined by the doctor individually.
The drug should be prescribed 2-4 tablets 2-3 times a day. The tablets should be taken after meals, without chewing, with plenty of liquid. The maximum daily dose should not exceed 1200 mg. In case of arterial hypotension, negative reactions from the gastrointestinal tract or the central nervous system, the initial dose may be reduced to 100 mg of pentoxifylline 3 times a day. In case of impaired renal function (creatinine clearance <30 ml / min), the dose is reduced by 50-70%, according to individual sensitivity. Patients with severe hepatic dysfunction also need to reduce dosage according to individual sensitivity. In patients with arterial hypotension, as well as in patients at risk of a sharp decrease in blood pressure (for example, with damage to the coronary arteries or severe stenosis of the cerebral arteries), treatment should be started with low doses, gradually increasing them until the onset of a therapeutic effect. The drug in tablets can be prescribed as an adjunct to parenteral administration or as maintenance therapy after its administration. The duration of treatment is determined by the doctor individually.
Application features:
At the first signs of the development of anaphylactic / anaphylactoid reactions, treatment should be discontinued and seek medical attention from a doctor. In the case of using pentoxifylline, patients with chronic heart failure should first achieve a phase of blood circulation compensation. In patients with diabetes mellitus and receiving treatment with insulin or oral hypoglycemic agents, the use of high doses of the drug may increase the effect of these drugs on blood sugar levels (see Section “Interaction with other drugs and other types of interactions”). In these cases, the dose of insulin or oral antidiabetic agents should be reduced and the patient carefully looked after.
The drug should be used with caution in patients who are simultaneously using pentoxifylline and ciprofloxacin (see Section “Interaction with other medicinal products and other types of interactions”). Patients with systemic lupus erythematosus (SLE) or with other connective tissue diseases should be prescribed pentoxifylline only after careful consideration of the possible risks and benefits. Since there is a risk of developing aplastic anemia during treatment with pentoxifylline, regular monitoring of a complete blood count is necessary. In patients with renal insufficiency (creatinine clearance less than 30 ml / min) or severe liver dysfunction, the excretion of pentoxifylline may be delayed. We need proper monitoring.
Particularly careful observation is necessary for patients:
- With severe cardiac arrhythmias;
- With myocardial infarction;
- With arterial hypotension;
- With severe atherosclerosis of cerebral and coronary vessels, especially with concomitant arterial hypertension and cardiac arrhythmias. In such patients, when using the drug, attacks of angina pectoris, arrhythmias and arterial hypertension are possible.
- With renal failure (creatinine clearance below 30 ml / min);
- With severe hepatic impairment;
- With a high tendency to bleeding, due, for example, to treatment with anticoagulants or blood coagulation disorders. For bleeding – see section “Contraindications”;
- With a history of gastric and duodenal ulcers, patients who have recently undergone surgical treatment (increased risk of bleeding, and therefore requires systematic monitoring of hemoglobin and hematocrit levels)
Shelf life:
3 years.
3 years.
Storage conditions:
Store in its original packaging at a temperature not exceeding 25 ° C.
Store in its original packaging at a temperature not exceeding 25 ° C.
Produced in Ukraine
